YOLFTbeta
MAIA Biotechnology Inc.

MAIA Biotechnology Inc.

MAIA · AMEX · Healthcare / Biotechnology

1.00USD-0.01 (-0.99%)

Price History

Full chart

Market Stats

Previous Close1.01
Open1.01
Day Range1.00 – 1.04
52-Week Range0.87 – 3.19
Volume376.77K
Market Cap71.78M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.63
Dividend Yield0.00%
Beta0.26
50-Day Avg1.34
200-Day Avg1.50

About

MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Vlad Vitoc M.B.A., M.D.
  • Employees13
  • Headquarters444 West Lake Street, Chicago, IL, United States, 60606, USA
  • Websitehttps://maiabiotech.com

Leadership

  • Dr. Vlad Vitoc M.B.A., M.D.Co-Founder, President, CEO & Chairman of the Board of Directors · b. 1970
  • Mr. Jeffrey C. Himmelreich M.B.A.Head of Finance and Principal Financial & Accounting Officer · b. 1976
  • Dr. Sergei M. Gryaznov Ph.D.Chief Scientific Officer · b. 1960
  • Linda MoreiraCompany Secretary

Financials

Income Statement

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-000000
Operating Income-6.92M-6.98M-7.79M-16.18M-20.18M-16.96M-24.27M
EBITDA242-6.97M-11.75M-15.76M-19.77M-23.25M-22.40M
Net Income-6.49M-6.64M-12.50M-15.77M-19.77M-23.25M-22.40M
R&D1.91M1.41M3.45M8.93M11.11M10.01M14.55B
Interest Expense031.55K827.54K6.97K6.86K570

Balance Sheet

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets1.73M746.50K11.33M12.02M7.57M10.16M9.70M
Total Liabilities409.74K2.36M2.15M3.51M7.09M6.52M7.33M
Total Equity-172.87K-3.34M9.18M8.51M477.51K3.63M2.38M
Cash1.71M663.46K10.57M10.95M7.15M9.60M8.66B
Total Debt34.17K463.75K-----
Net Debt-1.68M-199.70K-10.57M-10.95M-7.15M-9.60M-8.66B

Cash Flow

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-1.57M-1.84M-4.12M-12.10M-13.07M-15.70M-18.84M
Investing Cash Flow187.56K------
Financing Cash Flow2.22M798.05K14.03M12.48M9.27M18.18M17.91M
Capital Expenditure2000400
Free Cash Flow-1.57M-1.84M-4.12M-12.10M-13.07M-15.70M-18.84M
Dividends Paid-58.21K-----
FCF to OCF100.00%100.00%100.00%100.00%100.00%100.00%100.00%
Dividend Paid to FCF--3.16%-----

Earnings

Report DateDec 22, 2021Aug 8, 2022Nov 9, 2022Mar 24, 2023May 8, 2023Aug 8, 2023Nov 7, 2023Mar 21, 2024May 14, 2024Aug 9, 2024Nov 12, 2024Mar 24, 2025May 9, 2025Aug 8, 2025Nov 7, 2025Mar 23, 2026May 11, 2026Aug 10, 2026Nov 6, 2026
EPS Estimate0.000.00-0.49-0.41-0.42-0.43-0.38-0.39-0.39-0.41-0.47-0.35-0.18-0.25-0.19-0.13-0.18-0.11-0.13
EPS Actual-1.02-0.07-0.49-0.35-0.38-0.35-0.36-0.40-0.46-0.40-0.11-0.32-0.16-0.18-0.27-0.14-0.14-0.13-
Surprise--0.00%14.63%9.52%18.60%5.26%-2.56%-17.95%2.44%76.60%8.57%11.11%28.00%-42.11%-5.23%22.22%-18.18%-
Timing-After-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours-Pre-marketPre-market-

Key Statistics & Ratios

Market Cap71.78M
Enterprise Value52.71M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book3.88
EPS-0.63
Book Value0.34
Revenue (TTM)0
Gross Profit (TTM)0
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-218.68%
Return on Assets-92.10%
Shares Outstanding60.83M
Shares Float55.30M
Beta0.26
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 1 analystsTarget 12.00
  • Strong Buy
    1